

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DAWRAYS PHARMACEUTICAL (HOLDINGS) LIMITED

東瑞製藥(控股)有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2348)

RESIGNATION OF CHIEF EXECUTIVE OFFICER

This announcement is made by Dawnrays Pharmaceutical (Holdings) Ltd. (the “Company”, together with its subsidiaries, collectively the “Group”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

RESIGNATION OF CHIEF EXECUTIVE OFFICER

The board of directors (the “Board”) of the Company hereby announces that Mr. Wu Weixian (“Mr. Wu”) intends to focus on his other personal commitments, he has tendered his resignation as the chief executive officer of the Company (the “Chief Executive Officer”) as well as other directorships at the subsidiary level of the Company. Mr. Wu’s resignation will take effect at 5:00 pm on 11 September 2024 and thereafter. Mr. Wu will cease to hold any position in the Group.

Mr. Wu has confirmed that he has no disagreement with the Board and there are no other matters relating to his resignation that need to be brought to the attention of holders of securities of the Company or The Stock Exchange of Hong Kong Limited (the “Stock Exchange”).

The Company is in the process of identifying a suitable candidate to fill the vacancy of the Chief Executive Officer. The Company will make further announcement in this regard as and when appropriate and in accordance with the requirements under the Rules Governing the Listing of Securities on the Stock Exchange.

The Company would like to express its gratitude to Mr. Wu for his contribution to the Company during his tenure of office.

By Order of the Board
Dawnrays Pharmaceutical (Holdings) Limited
Li Kei Ling
Chairman

Hong Kong, 11 September 2024

As at the date of this announcement, the Board of the Company comprises two executive directors, namely Ms. Li Kei Ling and Mr. Hung Yung Lai; one non-executive director, namely Mr. Leung Hong Man; three independent non-executive directors, namely Mr. Lo Tung Sing Tony, Mr. Ede, Ronald Hao Xi and Ms. Lam Ming Yee Joan.

** for identification purpose only*